moxonidine has been researched along with Cardiometabolic Syndrome in 17 studies
moxonidine: structure given in first source
Cardiometabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effects of moxonidine and metformin on glycaemic control in patients with impaired glucose tolerance and signs of the metabolic syndrome." | 9.12 | Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. ( Almazov, VA; Chazova, I; Shlyakhto, E, 2006) |
| "Twenty-six patients with mild hypertension were treated with moxonidine and a hypocaloric diet for 3 months, while a second normotensive group (n = 26) were followed-up with calorie restriction alone." | 9.12 | The effect of moxonidine on endothelial dysfunction in metabolic syndrome. ( Cikim, AS; Cikim, K; Ozdemir, R; Temel, I; Topal, E, 2006) |
| " The advantages of imidazoline receptors in neuroprotective of moxonidine in patients with arterial hypertension, metabolic syndrome, and diabetes mellitus is discussed in detail." | 8.93 | [Renoprotecion With Metabolic Syndrome: the Possibility of Receptor Agonist Imidazoline Moxonidine]. ( Ostroumova, OD; Zykova, AA, 2016) |
| "A 6-month clinical study with active therapeutic intervention was carried out to evaluate the efficacy of moxonidine for the correction of arterial hypertension in 30 patients with metabolic syndrome." | 7.77 | Pecularities of prolonged use of moxonidine in patients with hypertension associated with metabolic syndrome. ( Borodulina, EV; Gridneva, TD; Kseneva, SI; Kulakova, NV; Semiglazova, TA; Tarasova, IV; Trifonova, OJ; Udut, VV, 2011) |
| "Moxonidine was mostly prescribed as an add-on treatment to other antihypertensives (81." | 6.76 | [The efficacy and safety of moxonidine in patients with metabolic syndrome (the O.B.E.Z.I.T.A. trial)]. ( Chroust, K; Krupicka, J; Soucek, M, 2011) |
| "Moxonidine is a centrally active imidazoline receptor agonist that effectively lowers blood pressure and has been shown to have beneficial effects on lipid and carbohydrate metabolism." | 5.32 | Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. ( Marsalek, P; Sharma, AM; Wagner, T, 2004) |
| "To compare the effects of moxonidine and metformin on glycaemic control in patients with impaired glucose tolerance and signs of the metabolic syndrome." | 5.12 | Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. ( Almazov, VA; Chazova, I; Shlyakhto, E, 2006) |
| "Twenty-six patients with mild hypertension were treated with moxonidine and a hypocaloric diet for 3 months, while a second normotensive group (n = 26) were followed-up with calorie restriction alone." | 5.12 | The effect of moxonidine on endothelial dysfunction in metabolic syndrome. ( Cikim, AS; Cikim, K; Ozdemir, R; Temel, I; Topal, E, 2006) |
| " The advantages of imidazoline receptors in neuroprotective of moxonidine in patients with arterial hypertension, metabolic syndrome, and diabetes mellitus is discussed in detail." | 4.93 | [Renoprotecion With Metabolic Syndrome: the Possibility of Receptor Agonist Imidazoline Moxonidine]. ( Ostroumova, OD; Zykova, AA, 2016) |
| "A 6-month clinical study with active therapeutic intervention was carried out to evaluate the efficacy of moxonidine for the correction of arterial hypertension in 30 patients with metabolic syndrome." | 3.77 | Pecularities of prolonged use of moxonidine in patients with hypertension associated with metabolic syndrome. ( Borodulina, EV; Gridneva, TD; Kseneva, SI; Kulakova, NV; Semiglazova, TA; Tarasova, IV; Trifonova, OJ; Udut, VV, 2011) |
| "Moxonidine was mostly prescribed as an add-on treatment to other antihypertensives (81." | 2.76 | [The efficacy and safety of moxonidine in patients with metabolic syndrome (the O.B.E.Z.I.T.A. trial)]. ( Chroust, K; Krupicka, J; Soucek, M, 2011) |
| "Moxonidine has unique effects on a number of cell types through this unusual cellular site of action." | 2.48 | Pharmacological properties of the central antihypertensive agent, moxonidine. ( Brown-Bryan, TA; Edwards, LP; Ernsberger, P; McLean, L, 2012) |
| " Similar responses were observed after oral dosing and in lean littermates." | 1.32 | The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. ( Ernsberger, P; Velliquette, RA, 2003) |
| "Using a rat model of metabolic syndrome X, we sought to separate the influence of these two receptors on glucose and lipid metabolism by using selective antagonists." | 1.32 | The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. ( Ernsberger, P; Koletsky, RJ; Velliquette, RA, 2003) |
| "Moxonidine is a centrally active imidazoline receptor agonist that effectively lowers blood pressure and has been shown to have beneficial effects on lipid and carbohydrate metabolism." | 1.32 | Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. ( Marsalek, P; Sharma, AM; Wagner, T, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Gasparik, V | 1 |
| Greney, H | 1 |
| Schann, S | 1 |
| Feldman, J | 1 |
| Fellmann, L | 1 |
| Ehrhardt, JD | 1 |
| Bousquet, P | 1 |
| El-Sayed, SS | 3 |
| Rezq, S | 3 |
| Alsemeh, AE | 3 |
| Mahmoud, MF | 3 |
| Skibitsky, VV | 1 |
| Fendrikova, AV | 1 |
| Pyhalova, NE | 1 |
| Sirotenko, DV | 1 |
| Ostroumova, OD | 1 |
| Zykova, AA | 1 |
| Fuckar, K | 1 |
| Lakusić, N | 1 |
| Cerovec, D | 1 |
| Minushkina, LO | 1 |
| Krupicka, J | 1 |
| Soucek, M | 1 |
| Chroust, K | 1 |
| Edwards, LP | 1 |
| Brown-Bryan, TA | 1 |
| McLean, L | 1 |
| Ernsberger, P | 4 |
| Kseneva, SI | 1 |
| Borodulina, EV | 1 |
| Semiglazova, TA | 1 |
| Kulakova, NV | 1 |
| Tarasova, IV | 1 |
| Trifonova, OJ | 1 |
| Gridneva, TD | 1 |
| Udut, VV | 1 |
| Velliquette, RA | 3 |
| Syrtlanova, ER | 1 |
| Gil'mutdinova, LT | 1 |
| Rayner, B | 1 |
| Koletsky, RJ | 1 |
| Sharma, AM | 1 |
| Wagner, T | 1 |
| Marsalek, P | 1 |
| Kossover, R | 1 |
| Previs, SF | 1 |
| Chazova, I | 1 |
| Almazov, VA | 1 |
| Shlyakhto, E | 1 |
| Topal, E | 1 |
| Cikim, AS | 1 |
| Cikim, K | 1 |
| Temel, I | 1 |
| Ozdemir, R | 1 |
4 reviews available for moxonidine and Cardiometabolic Syndrome
| Article | Year |
|---|---|
[Renoprotecion With Metabolic Syndrome: the Possibility of Receptor Agonist Imidazoline Moxonidine].
Topics: Animals; Antihypertensive Agents; Humans; Hypertension; Imidazoles; Imidazoline Receptors; Kidney; K | 2016 |
[Possibilities of the use of moxonidine in the treatment of arterial hypertension in patients with metabolic syndrome and diabetes].
Topics: Antihypertensive Agents; Biological Availability; Blood Pressure; Diabetes Mellitus, Type 2; Endothe | 2011 |
Pharmacological properties of the central antihypertensive agent, moxonidine.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Central Nervous System; Heart Failure; Humans; Hyp | 2012 |
Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Cardiovascular Dis | 2004 |
3 trials available for moxonidine and Cardiometabolic Syndrome
| Article | Year |
|---|---|
[The efficacy and safety of moxonidine in patients with metabolic syndrome (the O.B.E.Z.I.T.A. trial)].
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; | 2011 |
Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; G | 2006 |
The effect of moxonidine on endothelial dysfunction in metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Pressure Determination; Caloric Restriction; Combined Modality | 2006 |
10 other studies available for moxonidine and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Synthesis and biological evaluation of 2-aryliminopyrrolidines as selective ligands for I1 imidazoline receptors: discovery of new sympatho-inhibitory hypotensive agents with potential beneficial effects in metabolic syndrome.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Blood-Brain Barrier; Drug Discovery; Heart Rate; I | 2015 |
Moxonidine ameliorates cardiac injury in rats with metabolic syndrome by regulating autophagy.
Topics: Animals; Autophagy; Beclin-1; Imidazoline Receptors; Metabolic Syndrome; Rats; Sequestosome-1 Protei | 2023 |
Moxonidine ameliorates cardiac injury in rats with metabolic syndrome by regulating autophagy.
Topics: Animals; Autophagy; Beclin-1; Imidazoline Receptors; Metabolic Syndrome; Rats; Sequestosome-1 Protei | 2023 |
Moxonidine ameliorates cardiac injury in rats with metabolic syndrome by regulating autophagy.
Topics: Animals; Autophagy; Beclin-1; Imidazoline Receptors; Metabolic Syndrome; Rats; Sequestosome-1 Protei | 2023 |
Moxonidine ameliorates cardiac injury in rats with metabolic syndrome by regulating autophagy.
Topics: Animals; Autophagy; Beclin-1; Imidazoline Receptors; Metabolic Syndrome; Rats; Sequestosome-1 Protei | 2023 |
Moxonidine ameliorates cardiac injury in rats with metabolic syndrome by regulating autophagy.
Topics: Animals; Autophagy; Beclin-1; Imidazoline Receptors; Metabolic Syndrome; Rats; Sequestosome-1 Protei | 2023 |
Moxonidine ameliorates cardiac injury in rats with metabolic syndrome by regulating autophagy.
Topics: Animals; Autophagy; Beclin-1; Imidazoline Receptors; Metabolic Syndrome; Rats; Sequestosome-1 Protei | 2023 |
Moxonidine ameliorates cardiac injury in rats with metabolic syndrome by regulating autophagy.
Topics: Animals; Autophagy; Beclin-1; Imidazoline Receptors; Metabolic Syndrome; Rats; Sequestosome-1 Protei | 2023 |
Moxonidine ameliorates cardiac injury in rats with metabolic syndrome by regulating autophagy.
Topics: Animals; Autophagy; Beclin-1; Imidazoline Receptors; Metabolic Syndrome; Rats; Sequestosome-1 Protei | 2023 |
Moxonidine ameliorates cardiac injury in rats with metabolic syndrome by regulating autophagy.
Topics: Animals; Autophagy; Beclin-1; Imidazoline Receptors; Metabolic Syndrome; Rats; Sequestosome-1 Protei | 2023 |
[The Effectiveness of Combination Antihypertensive Therapy in Women With Hypothyroidism and the Metabolic Syndrome].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dihydrop | 2016 |
Rare psychotropic adverse event of moxonidine.
Topics: Antihypertensive Agents; Dreams; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles | 2009 |
Pecularities of prolonged use of moxonidine in patients with hypertension associated with metabolic syndrome.
Topics: Adrenocorticotropic Hormone; Antihypertensive Agents; Female; Humans; Hydrocortisone; Hypertension; | 2011 |
The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X.
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Clonidine; Disease Models, Animal; Female; Glucose | 2003 |
[The use of moxonidine in patients with essential hypertension combined with metabolic syndrome].
Topics: Adult; Antihypertensive Agents; Blood Glucose; Humans; Hypertension; Imidazoles; Insulin; Kinins; Ma | 2003 |
The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Benzofurans; Blood Pressure; Disease | 2003 |
Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biomarkers; Blood Glucose; Blood Pressure; | 2004 |
Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agon | 2006 |